IMRX Immuneering Corp Insider Trading

CSO Brett Matthew Hall purchases 6,035 shares of IMRX at $4.15 amid -59.3% decline from 52-week high

Brett Matthew Hall, Chief Scientific Officer, acquired 6,035 shares at $4.15 on 2026-06-15, increasing his holdings by 1.6% to 382,531 shares. This purchase occurs as the stock is down 59.3% from its 52-week high of $10.08 and has declined 20.5% over the past 30 days. His cross-ticker track record shows 4 prior open-market buys with a 90-day win rate of 75.00% and average 90-day return of +123.1%, suggesting a history of favorable entry timing. However, at IMRX specifically, his track record is mixed: three prior buys (2025-06-20, 2025-06-23, and 2026-01-15) generated strong 90-day returns ranging from +25.8% to +281.1%, but one buy (2024-03-20) resulted in a -48.2% 90-day decline. The company faces significant headwinds: current-quarter revenue is $0.00, full-year net income is negative at $-13.5M, and annual revenue growth is -100.0%, indicating a pre-revenue or revenue-loss state with no positive earnings trajectory visible.

CBO Brakewood buys 5.25K shares of IMRX at $4.76; stock down 47.6% from 52-week high as cluster buy emerges.

Harold Eugene Brakewood, Chief Business Officer, purchased 5,250 shares at $4.76 on 2026-01-16, more than doubling his stake from 5,800 to 11,050 shares (+90.5%). The timing coincides with material headwinds: the stock trades 47.6% below its 52-week high of $9.26, has declined 17.9% over 30 days, and the company reported zero quarterly revenue with a net loss of $14,964,875 and negative full-year results. However, this buy is reinforced by a cluster pattern—4 other insiders also purchased within the past 14 days—suggesting coordinated conviction at current levels. Brakewood's prior trade at IMRX on 2025-06-20 delivered a +256.3% 90-day return, establishing a track record of successful timing at this specific ticker, though his earlier 2024-03-22 buy declined 45.1%, illustrating that prior success is not guaranteed to repeat in a company burning cash.

Director Schall Thomas J. purchases 21,645 shares of IMRX at $4.67; stock down 48.4% from 52-week high amid unprofitable operations.

Director Thomas J. Schall purchased 21,645 shares at $4.67 on 2026-01-15, increasing his holdings by 40.9% to 74,530 shares. This buy occurs while the stock trades 48.4% below its 52-week high of $9.26 and has declined 15.4% in the past 30 days. The company reported zero revenue in the latest quarter and a net loss of $14,964,875.00 for the full fiscal year, with annual revenue down 100.0%. On his cross-ticker track record, Schall's prior 3 buys averaged 90-day returns of +110.1% with a 66.67% win rate; however, his same-ticker history at IMRX shows mixed timing—2 of 3 prior buys were well-timed at the 90-day mark, while one incurred a -44.6% loss. A cluster of 4 other insiders also bought within the past 14 days, indicating coordinated insider buying activity despite the company's deteriorating financial position and recent price weakness.

Chief Scientific Officer buys 2,298 shares of IMRX at $4.57; part of 4-insider cluster buy; stock down 50.5% from 52-week high

Hall Brett Matthew (Chief Scientific Officer) purchased 2,298 shares at $4.57, increasing holdings to 376,496 shares in a company generating $0.00 in latest quarterly revenue with $-14,964,875.00 net income. The stock is trading at $4.58, down 50.5% from its 52-week high and down 16.7% over the past 30 days. This purchase is part of a broader cluster pattern with 4 other insiders buying within the past 14 days, suggesting coordinated management confidence. In his prior two IMRX purchases (June 2025), Matthew's timing proved strong with 90-day returns of +68.7% and +281.1%, though a 2024 purchase returned -48.2% over 90 days; his cross-ticker track record shows 66.67% 90-day win rate with average 90d return of +155.5%, demonstrating a historical pattern of value recognition, though at a fundamentally challenged company.

Chief People Officer Leah R Neufeld bought 2,626 shares at $4.15; stock down 49.9% from 52-week high, 3 other insiders bought within 14 days.

Leah R Neufeld, Chief People Officer at Immuneering Corp, purchased 2,626 shares at $4.15 on 2026-01-13, increasing her holdings by 11.2% to 25,970 shares total. This transaction occurs as IMRX trades at $4.64, down 49.9% from its 52-week high and down 19.2% over 30 days, suggesting purchase near recent lows. The filing shows a cluster pattern: 3 other insiders also bought within the past 14 days, which may indicate coordinated confidence at current valuations. However, the company's fundamentals remain challenged—revenue is $0.00 in the latest quarter, annual revenue growth is -100.0%, and net income was negative at -$14,964,875.00, indicating the company is unprofitable and in early-stage or distressed operations. Against this context, multiple insider purchases may reflect either a belief in turnaround prospects or a routine compensation/equity program rather than a market-timing signal.

Director Feinberg bought 20,000 shares of IMRX at $4.35 on 2026-01-12; stock down 52.2% from 52-week high, post-transaction holdings 135,441 shares.

Peter Feinberg, a Director at Immuneering Corp, purchased 20,000 shares at $4.35 on 2026-01-12, expanding his holdings from 115,441 to 135,441 shares. The purchase occurred in a context of significant price pressure: the stock trades at $4.43, down 52.2% from the 52-week high and 23.4% over the past 30 days. At this ticker, Feinberg's prior five trades show mixed outcomes—his June 2025 purchase appreciated 228.8% at the 90-day mark, but his March 2024 and September 2025 purchases suffered declines; overall, 1 of 5 prior IMRX trades were well-timed at the 90-day mark. Fundamentally, the company faces headwinds: latest quarterly revenue is $0.00, net income is $-14,964,875.00, and annual revenue growth is -100.0%, indicating a material deterioration in the business profile. The buy signal from insider accumulation is notably weakened by both the weak execution track record at this specific ticker and the company's fundamental contraction.

Director Peter Feinberg buys 7,500 shares of IMRX at $6.67; stake rises 5.0% amid cluster buying by 3 other insiders.

Feinberg purchased 7,500 shares (7.5K shares) at $6.67 on 2025-10-03, increasing his holdings to 156,766 shares (156.8K shares), a 5.0% increase from his prior position. This buy occurs as part of a cluster of activity—3 other insiders also bought within the past 14 days—which often signals coordinated confidence in valuation or forward direction. However, context is mixed: the stock currently trades at $6.11, down 34.0% from its 52-week high of $9.26, though it has gained 10.9% over the past 30 days and 37.3% over 90 days. At the same ticker, Feinberg's prior trade outcomes have been inconsistent—a June 2025 buy returned 228.8% at the 90-day mark, but March 2024 buys returned -44.7% and -40.0% at 90 days, and he has achieved only a 1-of-3 well-timed rate on his IMRX trades. Fundamentally, the company reported zero revenue in its latest quarter, posted a net loss of $14,433,881.00 ($-14.4M) on an annual basis, with -100.0% annual revenue growth, and maintains a $158,481,571.04 ($158.5M) market cap. The combination of cluster buying activity and the director's willingness to accumulate despite deteriorating financials invites closer scrutiny of whether this reflects a positive forward view or is disconnected from underlying business performance.

CAO Morales Mallory bought 300 IMRX shares at $6.39; prior buys at this ticker lost -29.3% and -33.8% in 30 days

Morales Mallory, Chief Accounting Officer, purchased 300 shares of Immuneering Corp on 2025-10-01 at $6.39, adding to holdings of 27.5K shares. This represents a small incremental position increase of 1.1%. However, the timing is concerning: his two prior open-market purchases at IMRX in March 2024 declined -29.3% and -33.8% over the following 30 days, with neither well-timed at the 90-day mark. Additionally, his broader cross-ticker track record shows 2 prior buys with an average 30-day return of -31.5% and a 0.00% win rate over 90 days. The company itself faces headwinds, with zero revenue in the latest quarter and a net loss of $-14,433,881.00, along with -100.0% annual revenue growth. While 3 other insiders also bought within the past 14 days (a cluster pattern), the CAO's personal history of ill-timed purchases and the company's financial distress suggest this transaction warrants cautious scrutiny of underlying motivations and fundamentals.

Chief People Officer Leah R Neufeld buys 800 shares of IMRX at $6.38; cluster pattern with 3 other insiders buying within 14 days

Leah R Neufeld, Chief People Officer, purchased 800 shares at $6.38 on 2025-10-01, expanding her holdings from 22,544 to 23,344 shares. The transaction occurs within a cluster pattern—3 other insiders bought within the past 14 days—suggesting coordinated or near-simultaneous confidence assessment at the leadership level. However, context is mixed: Neufeld's cross-ticker track record shows her prior 2 buys averaged +23.8% over 90 days with a 50% win rate, but at IMRX specifically, her prior buy on 2025-07-02 returned +96.1% at 90 days while her 2024-03-20 buy fell -48.6%, indicating inconsistent stock-specific outcomes. The company operates with $0.00 revenue (latest quarter) and -$14.4M net income, with annual revenue declining -100%, raising fundamental questions about execution and near-term path to profitability that investors should weigh against insider accumulation patterns.

Chief Legal Officer Michael Bookman buys 1,020 shares at $6.83; 3 other insiders bought in past 14 days amid losses of $14.4M and -100% revenue decline.

Michael Bookman, Chief Legal Officer and Secretary, purchased 1,020 shares at $6.83 on 2025-10-01, increasing his holdings by 26.5% to 4,870 shares total. This transaction occurs as part of a cluster pattern: 3 other insiders also bought within the past 14 days, suggesting coordinated or reactive buying across the leadership group. Against this backdrop, Immuneering Corp reported zero revenue in its latest quarter, a full-year net loss of $14.4M, and annual revenue growth of -100.0%, indicating the company faces fundamental operational challenges. The stock is currently trading 29.5% below its 52-week high, though it has gained 9.0% over the past 30 days and 89.3% over 90 days. The cluster buy pattern combined with severe financial deterioration warrants examination of whether insiders possess material non-public information or are responding to a turnaround thesis not yet reflected in public disclosures.